Tags

Type your tag names separated by a space and hit enter

Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.
J Clin Psychopharmacol. 2008 Oct; 28(5):550-4.JC

Abstract

OBJECTIVE

Although many patients with obsessive-compulsive disorder (OCD) benefit from treatment with serotonin reuptake inhibitors (SRIs), it is estimated that 40% to 60% of them do not respond. The objective of the present study was to evaluate the efficacy of quetiapine added to baseline treatment with SRIs for the treatment of OCD in severely ill adult subjects.

METHOD

Forty patients (21 men, 19 women) with primary OCD according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria participated in a 12-week, double-blind, placebo-controlled trial. They were randomly assigned to dosages of quetiapine titrated up to 400 mg/d (n = 20) or to placebo (n = 20) in addition to their SRI treatment. During the continuation phase (weeks 6-12), subjects received different dosages between 400 and 600 mg/d depending on clinical response. At entry, all patients were unresponsive to at least 1 course of at least 12 weeks of treatment with SRIs at defined doses. The total Yale-Brown Obsessive-Compulsive Scale score was the primary efficacy parameter.

RESULTS

Intention-to-treat, last-observation-carried-forward analysis demonstrated a mean +/- SD decrease in Yale-Brown Obsessive-Compulsive Scale score of 5.2 +/- 5.4 in the quetiapine group and 3.9 +/- 4.9 in the placebo group. The analysis of treatment effects between the 2 groups showed no significant difference. There were no significant group differences in any of the other self-rating scales or clinician-administered rating scales.

CONCLUSIONS

In this study, augmentation of SRI treatment with quetiapine in severe OCD had no additional effect.

Authors+Show Affiliations

Department of Psychiatry and Psychotherapy, University of Luebeck, Ratzeburger Allee 160, D-23538 Luebeck, Germany. andreas.kordon@psychiatrie.uk-sh.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18794652

Citation

Kordon, Andreas, et al. "Quetiapine Addition to Serotonin Reuptake Inhibitors in Patients With Severe Obsessive-compulsive Disorder: a Double-blind, Randomized, Placebo-controlled Study." Journal of Clinical Psychopharmacology, vol. 28, no. 5, 2008, pp. 550-4.
Kordon A, Wahl K, Koch N, et al. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol. 2008;28(5):550-4.
Kordon, A., Wahl, K., Koch, N., Zurowski, B., Anlauf, M., Vielhaber, K., Kahl, K. G., Broocks, A., Voderholzer, U., & Hohagen, F. (2008). Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. Journal of Clinical Psychopharmacology, 28(5), 550-4. https://doi.org/10.1097/JCP.0b013e318185e735
Kordon A, et al. Quetiapine Addition to Serotonin Reuptake Inhibitors in Patients With Severe Obsessive-compulsive Disorder: a Double-blind, Randomized, Placebo-controlled Study. J Clin Psychopharmacol. 2008;28(5):550-4. PubMed PMID: 18794652.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. AU - Kordon,Andreas, AU - Wahl,Karina, AU - Koch,Nicole, AU - Zurowski,Bartosz, AU - Anlauf,Matthias, AU - Vielhaber,Kirsten, AU - Kahl,Kai G, AU - Broocks,Andreas, AU - Voderholzer,Ulrich, AU - Hohagen,Fritz, PY - 2008/9/17/pubmed PY - 2008/12/17/medline PY - 2008/9/17/entrez SP - 550 EP - 4 JF - Journal of clinical psychopharmacology JO - J Clin Psychopharmacol VL - 28 IS - 5 N2 - OBJECTIVE: Although many patients with obsessive-compulsive disorder (OCD) benefit from treatment with serotonin reuptake inhibitors (SRIs), it is estimated that 40% to 60% of them do not respond. The objective of the present study was to evaluate the efficacy of quetiapine added to baseline treatment with SRIs for the treatment of OCD in severely ill adult subjects. METHOD: Forty patients (21 men, 19 women) with primary OCD according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria participated in a 12-week, double-blind, placebo-controlled trial. They were randomly assigned to dosages of quetiapine titrated up to 400 mg/d (n = 20) or to placebo (n = 20) in addition to their SRI treatment. During the continuation phase (weeks 6-12), subjects received different dosages between 400 and 600 mg/d depending on clinical response. At entry, all patients were unresponsive to at least 1 course of at least 12 weeks of treatment with SRIs at defined doses. The total Yale-Brown Obsessive-Compulsive Scale score was the primary efficacy parameter. RESULTS: Intention-to-treat, last-observation-carried-forward analysis demonstrated a mean +/- SD decrease in Yale-Brown Obsessive-Compulsive Scale score of 5.2 +/- 5.4 in the quetiapine group and 3.9 +/- 4.9 in the placebo group. The analysis of treatment effects between the 2 groups showed no significant difference. There were no significant group differences in any of the other self-rating scales or clinician-administered rating scales. CONCLUSIONS: In this study, augmentation of SRI treatment with quetiapine in severe OCD had no additional effect. SN - 1533-712X UR - https://www.unboundmedicine.com/medline/citation/18794652/Quetiapine_addition_to_serotonin_reuptake_inhibitors_in_patients_with_severe_obsessive_compulsive_disorder:_a_double_blind_randomized_placebo_controlled_study_ L2 - https://doi.org/10.1097/JCP.0b013e318185e735 DB - PRIME DP - Unbound Medicine ER -